marble bone disease

(redirected from Malignant Osteopetrosis)
Also found in: Medical.

marble bone disease

[′mär·bəl ¦bōn di‚zēz]
(medicine)
Mentioned in ?
References in periodicals archive ?
Infantile malignant osteopetrosis (IMO) is a rare congenital disease that is characterized by an impaired function or differentiation of osteoclasts.
Preclinical studies of additional bone marrow-derived disorders are ongoing and target pyruvate kinase deficiency, leukocyte adhesion deficiency-I (LAD-I) and infantile malignant osteopetrosis.
Actimmune is approved by the Food and Drug Administration for use in children and adults with chronic granulomatous disease and severe, malignant osteopetrosis.
ACTIMMUNE is reportedly approved by the US FDA to reduce the severity of serious infections associated with Chronic Granulomatous Disease (CGD), a genetic disorder that affects the functioning of a type of white blood cell of the immune system, neutrophils or phagocytes; as well as to slow the worsening of severe, malignant osteopetrosis (SMO), a genetic disorder that affects normal bone formation causing the abnormal accumulation of bone material which tends to narrow the space inside bones.
The US FDA approved its use in children and adults with chronic granulomatous disease and severe, malignant osteopetrosis.
Vidara, which has operations both in Ireland and the US, markets Actimmune, a bioengineered form of a protein, which in the US is approved for use in children and adults with chronic granulomatous disease (CGD) and severe, malignant osteopetrosis (SMO).
Malignant osteopetrosis or autosomal recessive osteopetrosis (ARO) is characterized by severe osteosclerosis, pathologic fractures, hepatosplenomegaly, and pancytopenia, due to an osteoclast dysfunction that results in inadequate bone resorption.
Gamma Immunex (recombinant interferon beta 1) is an effective treatment for patients suffering from infectious diseases such as chronic granulomatous and malignant osteopetrosis.
InterMune's revenues are comprised of revenues from our HCV collaboration with Roche and sales of Actimmune(R), which is approved for two indications, chronic granulomatous disease (CGD) and severe, malignant osteopetrosis.
Interferon beta-1a (Avonex) and interferon beta-1b (Betaseron) are approved for multiple sclerosis; interferon gamma-1b (Actimmune) reduces the frequency and severity of infections associated with chronic granulomatous disease and delays progression of malignant osteopetrosis.
Interferon beta-1a (Avonex) and interferon beta-1b (Betaseron) are approved for treating multiple sclerosis; interferon gamma-1b (Actimmune) is used to reduce the frequency and severity of serious infections associated with chronic granulomatous disease and to delay the progression of malignant osteopetrosis.

Full browser ?